Skip to content

US · HAE · MEDICAL - DEVICES

Haemonetics Corporation (HAE) intrinsic value and stock valuation

$120.16as of 2026-11-21 · Mkt cap 3.8B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Haemonetics Corporation DCF and intrinsic value

InvestorsCraft values HAE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from HAE’s statements →

Haemonetics Corporation Graham Number

Graham Number: $27.99d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Boston, MA 02110 haemonetics.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$1.33B+8.9% 5y CAGRd
20122026
Net income
$97.3M+4.1% 5y CAGRd
20122026
Free cash flow
$260.4M+29.4% 5y CAGRd
20122026
Total equity
$796.3M+1.7% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$1.33B$1.36B$1.31B$1.17B$993.2M
Operating income$241.4M$221.8M$164.9M$156M$80.8M
Net income$97.3M$167.7M$117.6M$115.4M$43.4M
EPSd$2.06M$3.31M$2.29M$2.24M$844.8K
Operating cash flow$293.2M$181.7M$181.8M$273.1M$172.3M
Capital expenditure-$-32.78M-$-39.28M-$-66.3M-$-110.19M-$-96.51M
Free cash flow$260.4M$142.5M$115.5M$162.9M$75.8M
Total assets$2.4B$2.45B$2.2B$1.93B$1.86B
Total debt$1.22B$1.22B$807.8M$765.9M$780.8M
Net debt$979.1M$918M$629M$481.4M$521.3M
Total equity$796.3M$820.8M$960M$818M$749.4M
Cash and short-term investments$245.4M$306.8M$178.8M$284.5M$259.5M
Income statement
20262025202420232022
Revenue$1.33B$1.36B$1.31B$1.17B$993.2M
Cost of revenue$590.4M$582.3M$597.1M$545.8M$462.4M
Gross profit$743.6M$778.6M$711.9M$622.9M$530.8M
Research and development expenses$59.8M$69.4M$63M$58.6M$55.2M
Selling, general and administrative expenses$442.4M$422.1M$420.8M$374M$332.2M
Other expenses$0.00$65.3M$63.2M$34.3M$62.6M
Operating expenses$502.2M$556.7M$547M$466.8M$450M
Cost and expenses$1.09B$1.14B$1.14B$1.01B$912.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$28.7M$9.75M$13M$14.6M$17.1M
Depreciation and amortization$155.7M$108.9M$88.6M$84.8M$86.6M
Ebitda$312.5M$356M$295.5M$252M$191.7M
Operating income$241.4M$221.8M$164.9M$156M$80.8M
Total other income/expenses, net-$-113.37M-$-9.75M-$-13.02M-$-14.63M-$-17.12M
Income before tax$128M$212.1M$151.9M$141.4M$63.6M
Income tax expense$30.7M$44.4M$34.3M$26M$20.3M
Net income$97.3M$167.7M$117.6M$115.4M$43.4M
Weighted average shares outstanding$47.2M$50.3M$50.7M$50.8M$51.1M
Weighted average diluted shares outstanding$47.4M$50.7M$51.4M$51.4M$51.4M
Balance sheet
20262025202420232022
Cash and short-term investments$245.4M$306.8M$178.8M$284.5M$259.5M
Net receivables$216.9M$202.7M$206.6M$179.1M$159.4M
Inventory$306.4M$365.1M$317.2M$259.4M$293M
Total current assets$834.9M$935M$768.9M$769.7M$756M
Property, plant and equipment, net$305.8M$284.1M$366.6M$310.9M$258.5M
Goodwill and intangible assets$1.1B$1.06B$971.2M$742M$777.6M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.56B$1.52B$1.43B$1.17B$1.1B
Total assets$2.4B$2.45B$2.2B$1.93B$1.86B
Accounts payable$51.1M$67M$73.4M$63.9M$58.4M
Short-term debt$5.01M$303.6M$10.2M$11.8M$221.3M
Deferred revenue$42.3M$43.4M$31.2M$30.2M$26.8M
Total current liabilities$282.6M$578.1M$300.4M$251.8M$442.3M
Long-term debt$1.22B$921.2M$797.6M$754.1M$559.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.32B$1.05B$935.3M$865M$668M
Capital lease obligations$0.00$0.00$0.00$0.00$7.2M
Total liabilities$1.6B$1.63B$1.24B$1.12B$1.11B
Common stock$450K$480K$510K$500K$510K
Retained earnings$279.3M$352.2M$360.5M$253.2M$202.4M
Accumulated other comprehensive income (loss)-$-37.61M-$-55.08M-$-35.63M-$-30.38M-$-25.95M
Total equity$796.3M$820.8M$960M$818M$749.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.22B$1.22B$807.8M$765.9M$780.8M
Net debt$979.1M$918M$629M$481.4M$521.3M
Cash flow statement
20262025202420232022
Net income$97.3M$167.7M$117.6M$115.4M$43.4M
Depreciation and amortization$111.7M$115.6M$97.2M$93.3M$97.8M
Stock-based compensation$33.8M$29.6M$28.3M$25.6M$24.4M
Change in working capital-$-23.65M-$-91.98M-$-74.7M$25.5M-$-15.18M
Accounts receivable-$-14.88M$6.96M-$-24.19M-$-24.42M-$-34.97M
Inventory$47.4M-$-64.7M-$-60.06M$30.8M$24.3M
Accounts payable-$-16.57M$0.00$44.6M$39.8M$0.00
Net cash provided by operating activities$293.2M$181.7M$181.8M$273.1M$172.3M
Investments in property, plant and equipment-$-92.96M-$-39.28M-$-66.3M-$-110.19M-$-96.51M
Acquisitions, net$1.38M-$-107.61M-$-240.54M-$-2M$8.14M
Net cash used for investing activities-$-179.55M-$-161.9M-$-322.39M-$-143.79M-$-86.34M
Common stock issued$7.89M-$-1.91M$7.21M$0.00$0.00
Common stock repurchased-$-175M-$-225M$0.00-$-75M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-178.46M$108.8M$38.2M-$-100.36M-$-15.75M
Net change in cash-$-61.32M$128M-$-105.67M$25M$67.2M
Cash at end of period$245.4M$306.8M$178.8M$284.5M$259.5M
Operating cash flow$293.2M$181.7M$181.8M$273.1M$172.3M
Capital expenditure-$-32.78M-$-39.28M-$-66.3M-$-110.19M-$-96.51M
Free cash flow$260.4M$142.5M$115.5M$162.9M$75.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Haemonetics Corporation

        Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

        CEO
        Christopher A. Simon
        Employees
        3.01K
        Beta
        0.52

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Haemonetics Corporation (HAE)?

        Haemonetics Corporation (HAE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HAE undervalued?

        HAE trades at a price of $120.16 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.